app 4c, page-3

Good to see revenues increase in each of the last 4 quarters and revenues are up 30% over the previous 12 months. That is a testament to the good work the team has made.

Unfortunately the company doesn't split the costs between this business and trial costs.

Nevertheless, top line growth of 30% is nothing to be sneezed at.

I have cash burn running at around $400k but given the patient dosing phase of the trial was done in the last quarter I expect the cash burn to be less in Q4 and even less in Q1 next year.

So IMO they have around 7-9 months of cash left.

Of course if the oppies come into play that will help. But if the results are as good as most expect and the SP responds accordingly, they could go and raise a few mill $$ at hopefully 10c+ without causing too much dilution.

Either way, good to see the medical supply business performing well.